|
|
|
|
Archives
|
Entry
|
Author
|
Date
|
Location
|
|
FDA vs. Drug Ads: Cut the Kids and Dogs, Spell Out Side Effects
|
Arlene Weintraub |
02/06/12 |
National
|
|
Optimer, Following Pfizer’s Playbook, Has Big Plans for Antibiotic
|
Luke Timmerman |
01/31/12 |
San Diego
|
|
Four Themes to Watch in Personalized Medicine
|
Jonathan Sheffi |
01/30/12 |
San Francisco
|
|
Biotech Is Raising More Cash, But Don’t Be Fooled: Startups are Hurting
|
Luke Timmerman |
01/23/12 |
National
|
|
Report: UCSF Chancellor Proposes Autonomy in State University System
|
Luke Timmerman |
01/20/12 |
San Francisco
|
|
Clarus Ventures Adjusts to Unpredictable Biotech World
|
Luke Timmerman |
01/20/12 |
Boston
|
|
J&J Opens San Diego Biotech Startup Center, Says ‘No Strings Attached’
|
Luke Timmerman |
01/18/12 |
San Diego
|
|
Medivation Fails Alzheimer’s Trial, Pfizer Drops Out of Partnership
|
Luke Timmerman |
01/17/12 |
San Francisco
|
|
Knome Names New CEO, Cuts Deal With Johns Hopkins to Analyze 1,000 Genomes
|
Luke Timmerman |
01/09/12 |
Boston
|
|
Aveo (Barely) Passes Study With Kidney Cancer Drug, Stock Falls
|
Luke Timmerman |
01/03/12 |
Boston
|
|
Editor’s Picks: Xconomy Boston’s Top 20ish Stories of 2011
|
Gregory T. Huang |
12/28/11 |
Boston
|
|
MIT-Born Enumeral Advances Human-Based Method for Hunting Drugs
|
Arlene Weintraub |
12/20/11 |
New York
|
|
Trius Antibiotic Passes Pivotal Study Against Pfizer’s Zyvox
|
Luke Timmerman |
12/19/11 |
San Diego
|
|
AesRx Navigates “Valley of Death” to Get Sickle Cell Drug Into Trials
|
Arlene Weintraub |
12/14/11 |
Boston
|
|
Alnylam Racing to Prove RNAi Works, For a Disease You’ve Never Heard Of
|
Luke Timmerman |
12/13/11 |
Boston
|
|
Lpath Looks to Raise $10 Million Through Secondary Offering
|
Bruce V. Bigelow |
12/08/11 |
San Diego
|
|
Buyouts, Quantified Health, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
12/01/11 |
San Diego
|
|
MSU Bioeconomy Institute Snags State and Federal Funding For Proof of Concept Center
|
Sarah Schmid |
11/29/11 |
Detroit
|
|
Pfizer Acquires Excaliard, an Isis Spinout With Drug to Fight Excessive Scarring
|
Luke Timmerman |
11/22/11 |
San Diego
|
|
Rempex Raises $67.5M, Vertex Shares Tumble, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
11/10/11 |
San Diego
|
|
The Stroke Prevention War is On: FDA Approves J&J/Bayer Contender
|
Arlene Weintraub |
11/07/11 |
New York
|
|
Groupon: The IPO With More Sizzle, and Money, Than the Entire Biotech IPO Class of 2011
|
Luke Timmerman |
11/07/11 |
National
|
|
Sanford-Burnham Joins Fold at Pfizer’s Centers for Therapeutic Innovation
|
Bruce V. Bigelow |
11/03/11 |
San Diego
|
|
Biopharma Industry Meetings Could Use Some Fresh Voices
|
Stewart Lyman |
11/01/11 |
Seattle
|
|
The Cancer Drug Dark Ages Are Coming to an End
|
Luke Timmerman |
10/31/11 |
National
|
|
Illumina Leads $8M Investment in GenoLogics to Help Manage DNA Data Overload
|
Luke Timmerman |
10/20/11 |
Seattle
|
|
NextBio Sees Growth in Next Market: Physicians Seeking Help Interpreting Individual Genomes
|
Luke Timmerman |
10/18/11 |
San Francisco
|
|
Computers vs. Humans: A Recap of Xconomy’s New York Life Sciences 2031
|
Arlene Weintraub |
10/14/11 |
New York
|
|
Join Xconomy Tonight for New York Life Sciences 2031
|
Arlene Weintraub |
10/13/11 |
New York
|
|
Amgen Mulls R&D Cuts, Thong Le Named WBBA Chairman, NanoString’s Version 2.0, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
10/13/11 |
Seattle
|
|
Page 1 of
13 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.